Teva Respiratory launches AirDuo Digihaler, ArmonAir Digihaler
Teva Respiratory is unveiling AirDuo Digihaler (fluticasone propionate and salmeterol) inhalation powder and ArmonAir Digihaler (fluticasone propionate) inhalation powder, two digital maintenance inhalers for patients with asthma.
AirDuo Digihaler is used to control symptoms of asthma and to prevent symptoms such as wheezing in people 12 years of age and older. ArmonAir Digihaler is for the long-term treatment of asthma in patients 12 years and older. AirDuo Digihaler and ArmonAir Digihaler are not used to relieve sudden breathing problems from asthma and will not replace the need for a rescue inhaler, the company said.
“Being able to now offer AirDuo Digihaler and ArmonAir Digihaler to patients is an exciting step forward for Teva and one that we are extremely proud of,” said Brendan O’Grady, Teva executive vice president, North America commercial. “With the launch of these two maintenance products, we’re now able to offer the full Digihaler portfolio to patients, potentially allowing them to gain an even deeper understanding of their overall asthma treatment regimen due in part to the data collection capabilities of the Digihaler portfolio of products.”
Both products contain built-in Bluetooth Wireless Technology, which connects to a companion mobile app and provides data on inhaler use, which is recorded as an event when the cap is opened or a patient inhales. AirDuo Digihaler and ArmonAir Digihaler are part of Teva’s Digihaler portfolio, which also includes ProAir Digihaler, the first and only digital rescue inhaler indicated in patients four years or older for the treatment or prevention of bronchospasm who have reversible obstructive airway disease, and for prevention of exercise-induced bronchospasm.
“The launch of AirDuo Digihaler and ArmonAir Digihaler completes our portfolio of digitally connected inhalers and allows Teva to provide maintenance and rescue digital inhaler options to the United States respiratory community, especially in a time when digital health tools are more important than ever,” said Sven Dethlefs, Teva executive vice president, global marketing & portfolio. “The full Digihaler family is a major step forward for digital health technologies in helping to transform patient care, and we hope it will enable patients and their healthcare providers to better inform treatment decisions. For Teva, the Digihaler launch is the starting point for new software-based innovations in respiratory, moving treatment options beyond new therapeutic entities.”
The Wholesale Acquisition Cost for AirDuo Digihaler in the doses 55/14 mcg and 113/14 mcg is $399 and the WAC price for the 232/14 mcg dose is $449. The WAC price of ArmonAir Digihaler in the doses 55 mcg and 113 mcg is $239 and the WAC price for the 232 mcg dose is $299. Actual costs to individual patients and providers for both products are anticipated to be lower than WAC because WAC does not account for additional rebates and discounts that may apply. Savings on out-of-pocket costs may vary depending on the patient’s insurance payer and eligibility for participation in the assistance program.